Alpha-lipoic acid (ALA, thioctic acid) is a naturally occurring organosulfur compound that serves as an essential cofactor for mitochondrial energy metabolism and stands as one of the most unique antioxidants known to biochemistry — it is both water-soluble and fat-soluble, allowing it to operate in every compartment of every cell in the body, a property shared by no other common antioxidant. ALA is produced endogenously in small amounts by mitochondrial lipoic acid synthase and is also obtained from dietary sources including red meat, organ meats (particularly liver and kidney), spinach, broccoli, tomatoes, and brewer's yeast. As a supplement, alpha-lipoic acid has gained significant clinical and popular attention across multiple therapeutic domains: it is a first-line treatment for diabetic neuropathy in Germany (where it has been prescribed since 1966 under the brand name Thioctacid), an insulin sensitizer, a heavy metal chelator central to the Andy Cutler Protocol for mercury detoxification, a neuroprotective agent investigated in multiple sclerosis and Alzheimer's research, and a general antioxidant supplement. ALA exists as two enantiomers — R-lipoic acid (the biologically active form naturally produced by the body and found in food) and S-lipoic acid (an artifact of chemical synthesis not found in nature). Most commercially available supplements contain racemic ALA — a 50:50 mixture of R and S forms — though pure R-ALA supplements are available at higher cost and are argued by some to be superior. Perhaps ALA's most remarkable biochemical property is its role as an antioxidant recycler: when reduced to dihydrolipoic acid (DHLA) by mitochondrial enzymes, it regenerates other antioxidants including vitamin C, vitamin E, coenzyme Q10, and glutathione, earning it the designation "universal antioxidant" from UC Berkeley researcher Lester Packer.
What the Community Wants You to Know
Take ALA on an empty stomach — food reduces absorption by about 30%. The catch is that ALA on an empty stomach causes nausea in some people. If this happens, try taking it with a very small amount of food (a few crackers) to reduce GI distress while minimizing the absorption penalty.
'All ALA supplements are the same' — most supplements contain racemic ALA (50/50 R and S forms), but only R-ALA is the biologically active form your body naturally produces. Pure R-ALA supplements have higher bioavailability and potency per milligram, but cost more. If using racemic ALA, roughly double the dose compared to pure R-ALA.
ALA is potentially fatal to children at relatively low doses (~25mg/kg). If you have ALA supplements in your home and have children, store them with the same security as medications. A bottle of 600mg capsules is a serious poisoning risk for a toddler.
Safety at a Glance
High Risk- Taking ALA Correctly
- Take on an empty stomach — food reduces ALA absorption by approximately 30%. Take 30-60 minutes before meals or 2 hou...
- Toxicity: Acute Toxicity at Supplement Doses At standard supplement doses (300-600mg/day), alpha-lipoic acid is generally well-...
- Overdose risk: Overdose Profile in Adults Fatal ALA overdose in adults is extremely rare. The compound has a wid...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
Oral
Duration
Oral
Total: 4 hrs – 6 hrsHow It Feels
The Alpha-Lipoic Acid Experience
Describing "what ALA feels like" requires an immediate disclaimer: for most people, it does not feel like anything. ALA is not a substance you take for the experience. It is a substance you take for what it does at a cellular level — scavenging radicals, regenerating glutathione, improving mitochondrial function, chelating metals — none of which produces a perceptible subjective state. If piracetam is subtle, ALA is invisible.
Onset (30-60 minutes)
After taking 300-600mg of ALA on an empty stomach, the most immediately noticeable effect in many people is mild nausea — a faintly queasy, empty-stomach sensation that can range from barely perceptible to genuinely uncomfortable. This is the paradox of ALA supplementation: optimal absorption requires an empty stomach, but the compound is a mild gastric irritant. Taking it with a small amount of food reduces the nausea but also reduces absorption by about 30%.
Beyond the possible GI effects, there is nothing to subjectively observe at the onset. No mood shift, no energy boost, no cognitive change. The ALA has been absorbed and is being rapidly metabolized (half-life 30-60 minutes), distributed to mitochondria throughout the body, and reduced to DHLA by intracellular enzyme systems. All of this is happening with biochemical precision and zero phenomenological footprint.
Peak (1-2 hours)
The "peak" of ALA, if it can be called that, is an absence rather than a presence. Some users — particularly those with blood sugar instability or prediabetes — may notice slightly more stable energy levels or a reduced tendency toward the post-meal energy crash. Diabetic neuropathy patients on high-dose ALA may notice a gradual reduction in neuropathic symptoms (tingling, burning, numbness) over weeks of consistent use, though this is a clinical improvement rather than a subjective "experience."
For the chelation community, the ALA experience is defined by the chelation round protocol: taking ALA every 3 hours around the clock for 3+ days. During chelation rounds, some individuals report increased fatigue, mild "detox symptoms" (joint pain, headache, irritability), or conversely, increased mental clarity and energy. These effects are attributed to the mobilization and excretion of heavy metals and vary enormously between individuals.
The Long-Term Perspective
Where ALA's effects become most apparent is in the retrospective assessment after weeks or months of consistent use. Users frequently report not so much that they feel better on ALA, but that they felt worse when they stopped — a subtle cognitive fog, a return of energy fluctuations, or a slow degradation of the wellbeing improvements they had not consciously attributed to ALA until it was removed.
This retrospective recognition is the hallmark of supplements that work at the cellular and metabolic level rather than at the neurotransmitter level. You do not feel your glutathione being regenerated or your mitochondrial electron transport chain operating more efficiently. But over time, the cumulative effect of healthier cells — better energy production, reduced oxidative damage, more efficient detoxification — manifests as a general improvement in baseline function that is real but difficult to attribute to any single moment of subjective experience.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(6)
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Nausea suppression— Nausea suppression is the pharmacological reduction or elimination of nausea and the urge to vomit, ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
Cognitive & Perceptual Effects
Cognitive(2)
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Rejuvenation— A renewed sense of physical vitality, mental freshness, and emotional restoration that can emerge du...
Community Insights
Dosage Guidance(2)
Take ALA on an empty stomach — food reduces absorption by about 30%. The catch is that ALA on an empty stomach causes nausea in some people. If this happens, try taking it with a very small amount of food (a few crackers) to reduce GI distress while minimizing the absorption penalty.
Based on 1 community posts · 0 combined upvotes
ALA has a very short half-life (30-60 minutes). For antioxidant purposes, split your daily dose into 2-3 administrations throughout the day. A single morning dose of 600mg provides a brief spike in blood levels followed by many hours of essentially zero ALA.
Based on 1 community posts · 0 combined upvotes
Common Misconceptions(2)
'All ALA supplements are the same' — most supplements contain racemic ALA (50/50 R and S forms), but only R-ALA is the biologically active form your body naturally produces. Pure R-ALA supplements have higher bioavailability and potency per milligram, but cost more. If using racemic ALA, roughly double the dose compared to pure R-ALA.
Based on 1 community posts · 0 combined upvotes
'ALA is just another antioxidant like vitamin C or E' — ALA is unique among antioxidants because it is both water-soluble AND fat-soluble, works in every cellular compartment, AND regenerates other antioxidants (vitamins C and E, glutathione, CoQ10). No other common antioxidant does all three.
Based on 1 community posts · 0 combined upvotes
Harm Reduction(2)
ALA is potentially fatal to children at relatively low doses (~25mg/kg). If you have ALA supplements in your home and have children, store them with the same security as medications. A bottle of 600mg capsules is a serious poisoning risk for a toddler.
Based on 1 community posts · 0 combined upvotes
Do NOT start ALA chelation if you still have mercury amalgam dental fillings. ALA will chelate mercury directly from the fillings into your bloodstream, dramatically increasing your mercury exposure. Remove all amalgams first (with a biological/SMART-certified dentist), wait at least 3 months, then begin chelation.
Based on 1 community posts · 0 combined upvotes
Combination Warnings(1)
If you are diabetic and take insulin or sulfonylureas, monitor your blood sugar carefully when starting ALA. ALA enhances insulin sensitivity and can cause hypoglycemia. Start with a lower dose (100-200mg/day) and work up gradually, checking blood sugar frequently.
Based on 1 community posts · 0 combined upvotes
Community Wisdom(1)
If following the Andy Cutler chelation protocol for mercury, the most important rule is: dose ALA on schedule, every 3 hours around the clock, for the entire chelation round. Missing a dose mid-round can mobilize mercury without excreting it, potentially redistributing it to the brain. This means setting alarms to take ALA during the night.
Based on 1 community posts · 0 combined upvotes
Pharmacology
Mechanism of Action
Alpha-lipoic acid operates through a diverse and interconnected set of biochemical mechanisms that span energy metabolism, antioxidant defense, metal chelation, and cell signaling.
Mitochondrial Cofactor Role
ALA's most fundamental biochemical function is as an essential cofactor for mitochondrial enzyme complexes involved in energy metabolism:
- Pyruvate dehydrogenase complex: converts pyruvate to acetyl-CoA, linking glycolysis to the citric acid cycle — this is the gateway step for aerobic energy production
- Alpha-ketoglutarate dehydrogenase complex: a key enzyme within the citric acid cycle itself
- Branched-chain alpha-ketoacid dehydrogenase complex: involved in amino acid metabolism
In these enzyme complexes, the lipoic acid moiety is covalently attached to a lysine residue (forming lipoyllysine) and functions as a "swinging arm" that transfers acyl groups and electrons between active sites.
Redox Cycling and Antioxidant Activity
ALA is reduced intracellularly to dihydrolipoic acid (DHLA) by mitochondrial lipoamide dehydrogenase (using NADH) and by cytoplasmic thioredoxin reductase (using NADPH). The ALA/DHLA redox couple has a reduction potential of -0.32V, making DHLA one of the most potent biological reducing agents.
The ALA/DHLA system provides antioxidant protection through multiple mechanisms:
- Direct radical scavenging: both ALA and DHLA neutralize reactive oxygen species (ROS) including hydroxyl radicals, singlet oxygen, peroxynitrite, and hypochlorous acid
- Metal chelation: ALA chelates redox-active metals (iron, copper) that would otherwise catalyze radical formation via Fenton chemistry
- Amphiphilicity: as both water-soluble and fat-soluble, ALA/DHLA can quench radicals in aqueous (cytoplasm, blood) and lipid (membranes, lipoproteins) compartments — a unique property among biological antioxidants
Antioxidant Network Regeneration
ALA's most celebrated biochemical property is its ability to regenerate other antioxidants:
- Glutathione: DHLA reduces oxidized glutathione (GSSG) back to reduced glutathione (GSH), the body's most abundant endogenous antioxidant. ALA also increases glutathione synthesis by enhancing cysteine uptake into cells
- Vitamin C (ascorbate): DHLA regenerates dehydroascorbic acid back to ascorbate
- Vitamin E (tocopherol): DHLA regenerates the tocopheroxyl radical back to tocopherol (indirectly, via vitamin C regeneration)
- Coenzyme Q10 (ubiquinone): ALA/DHLA participates in the regeneration of reduced CoQ10
This cascading regeneration of the antioxidant network led Lester Packer to describe ALA as the "antioxidant of antioxidants."
Heavy Metal Chelation
ALA contains two sulfhydryl groups (when reduced to DHLA) that form stable dithiol complexes with heavy metals, including:
- Mercury (Hg2+): the primary target in the Andy Cutler chelation protocol
- Arsenic (As3+): ALA chelates trivalent arsenic species
- Cadmium (Cd2+) andlead (Pb2+): chelated by DHLA's vicinal dithiol structure
The Andy Cutler Protocol uses frequent, low-dose ALA (every 3 hours around the clock, including waking at night) to maintain steady blood levels for continuous chelation, as ALA's short half-life means that infrequent dosing can mobilize mercury without sustaining the blood levels needed to transport it out of the body — potentially redistributing mercury to sensitive organs.
Insulin Sensitization and Glucose Metabolism
ALA activates AMP-activated protein kinase (AMPK), a master metabolic regulator that:
- Enhances GLUT4 translocation to the cell surface, increasing glucose uptake independent of insulin
- Increases fatty acid oxidation
- Improves insulin receptor sensitivity
These effects underlie ALA's clinical use in diabetic neuropathy, where it improves both nerve function and glycemic control.
Anti-inflammatory Signaling
ALA inhibits activation of nuclear factor kappa-B (NF-kB), a transcription factor that drives the expression of pro-inflammatory cytokines, adhesion molecules, and inducible enzymes. ALA also activatesNrf2 (nuclear factor erythroid 2-related factor 2), which upregulates the expression of endogenous antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase.
Pharmacokinetics
- Oral bioavailability: approximately 30% for racemic ALA; R-ALA has higher bioavailability (40-50%) than S-ALA due to preferential absorption
- Time to peak plasma concentration (Tmax): 30-60 minutes; highly affected by food — take on an empty stomach for optimal absorption
- Elimination half-life: 30 minutes to 1 hour (very short, necessitating multiple daily doses for sustained effects)
- Metabolism: extensive first-pass hepatic metabolism via beta-oxidation of the valeric acid side chain, S-methylation, and conjugation
- Food effect: co-administration with food reduces peak plasma concentration by approximately 30% and delays Tmax; this is why empty stomach administration is consistently recommended
Detection Methods
Alpha-lipoic acid is not tested for on any drug screening panel — workplace, clinical, forensic, or sports. ALA is a naturally occurring compound present in the human body as a normal component of mitochondrial metabolism, and it is also found in common foods (red meat, spinach, broccoli). Its detection in biological samples is not indicative of supplementation or any abnormality. Analytical detection is possible via HPLC or LC-MS/MS for pharmacokinetic research purposes, but this is never performed in drug testing contexts. ALA will not trigger false positives for any class of controlled substances. It is not relevant to drug testing in any context.
Interactions
No documented interactions.
History
Discovery and Identification
The story of alpha-lipoic acid begins in 1937, when Esmond Emerson Snell and colleagues identified a bacterial growth factor in potato extract that was required for the growth of certain microorganisms. This unknown factor was designated the**"potato growth factor"** and later the**"pyruvate oxidation factor,"** reflecting its role in oxidative metabolism.
Isolation and Characterization
In 1951,Lester J. Reed and colleagues at the University of Texas at Austin achieved the landmark isolation and structural characterization of this factor, requiring10 tons of beef liver residue to obtain just 30 milligrams of the pure compound. Reed named italpha-lipoic acid (from the Greek "lipos" meaning fat, reflecting its lipid solubility) and determined its structure as a cyclic disulfide — a five-membered dithiolane ring attached to a valeric acid chain. This identification was a triumph of mid-century biochemistry and earned Reed international recognition.
Role in Mitochondrial Metabolism
Throughout the 1950s and 1960s, Reed and other researchers established ALA's role as an essential cofactor for the pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase enzyme complexes — critical enzymes that link glycolysis to the citric acid cycle, forming the foundation of aerobic energy production in all eukaryotic cells.
Clinical Use in Diabetic Neuropathy
In 1966, alpha-lipoic acid wasapproved in Germany for the treatment of diabetic peripheral neuropathy under the brand nameThioctacid (manufactured by MEDA/Viatris). Germany has the longest clinical track record with ALA for this indication, with large-scale trials including the ALADIN (Alpha-Lipoic Acid in Diabetic Neuropathy) series demonstrating significant improvement in neuropathic symptoms with intravenous and oral ALA. ALA remains a first-line treatment for diabetic neuropathy in German clinical practice.
The Universal Antioxidant
In the 1990s,Lester Packer at the University of California, Berkeley, championed ALA as the**"universal antioxidant"** — coining the term to describe ALA's unique ability to function in both aqueous and lipid environments and to regenerate other antioxidants (vitamins C and E, glutathione, CoQ10). Packer's research and advocacy significantly elevated ALA's profile in the antioxidant supplement market and in academic antioxidant research.
The Andy Cutler Protocol
In the late 1990s-2000s,Andrew Hall Cutler, PhD (a Princeton-educated chemist), developed a protocol for mercury detoxification using frequent, low-dose ALA chelation. Cutler, who attributed his own chronic health issues to mercury exposure from dental amalgams, published**"Amalgam Illness: Diagnosis and Treatment"** (1999) and built a substantial following in autism, chronic fatigue, and chronic illness communities. The Cutler Protocol emphasizes taking ALA every 3 hours around the clock (to maintain steady chelation without redistribution) in rounds of 3+ days followed by rest periods, starting at very low doses (12.5-25mg) and increasing gradually. Despite limited formal clinical validation, the protocol has thousands of adherents worldwide and has spawned dedicated online communities.
Modern Supplement Market
By the 2010s and 2020s, alpha-lipoic acid had become one of the most widely sold antioxidant supplements globally, available in racemic and R-ALA forms, with applications marketed for:
- Antioxidant and anti-aging support
- Blood sugar management and insulin sensitivity
- Neuroprotection and cognitive support
- Heavy metal detoxification
- Weight management (via AMPK activation)
- Skin health and anti-aging (topical formulations)
Annual global ALA supplement sales now exceed hundreds of millions of dollars, with growth driven by the expanding diabetic population, growing awareness of environmental toxin exposure, and the broader antioxidant supplement trend.
Harm Reduction
Taking ALA Correctly
- Take on an empty stomach — food reduces ALA absorption by approximately 30%. Take 30-60 minutes before meals or 2 hours after
- Split doses — ALA has a very short half-life (30-60 minutes). For antioxidant and neuroprotective purposes, divide the daily dose into 2-3 administrations rather than taking it all at once
- R-ALA vs racemic ALA: R-ALA is the biologically active form and has higher bioavailability. If using racemic ALA (the standard, less expensive form), roughly double the dose compared to pure R-ALA
Diabetic Patients
- Monitor blood glucose carefully when starting ALA supplementation. ALA enhances insulin sensitivity and can cause hypoglycemia, particularly in patients on insulin or sulfonylureas
- Discuss ALA supplementation with your endocrinologist before starting
- Consider starting at a lower dose (100-200mg/day) and increasing gradually
Chelation Safety (Andy Cutler Protocol)
If using ALA for mercury chelation:
- Never take ALA sporadically if you have mercury amalgam fillings or known mercury exposure. Irregular dosing can mobilize mercury without maintaining the blood levels needed to excrete it, potentially redistributing mercury to the brain
- Follow the Cutler Protocol precisely: dose every 3 hours around the clock (including setting alarms to dose during the night) for chelation rounds of 3+ days, followed by equal or longer rest periods
- Remove all mercury amalgam dental fillings BEFORE beginning ALA chelation — ALA will chelate mercury from fillings into the bloodstream
- Supplement essential minerals (zinc, magnesium, vitamin C, vitamin E) during chelation rounds, as ALA chelates beneficial minerals alongside toxic ones
- Start with the lowest effective dose (typically 12.5-25mg every 3 hours) and increase gradually over successive rounds
Keep Away from Children
ALA can be fatal to children at relatively low doses (~25 mg/kg). Store supplements securely and treat ALA with the same caution as any medication with pediatric toxicity potential.
Interactions
- Take ALA at a different time from thyroid medications (levothyroxine) — ALA may interfere with thyroid hormone absorption or metabolism
- Inform your oncologist if you are taking ALA during cancer treatment — the antioxidant effects may theoretically interact with oxidative-stress-dependent therapies
- ALA may potentiate the effects of blood sugar-lowering supplements and medications (berberine, metformin, insulin)
Toxicity & Safety
Acute Toxicity at Supplement Doses
At standard supplement doses (300-600mg/day), alpha-lipoic acid is generally well-tolerated with a favorable safety profile. The most common adverse effects are mild and gastrointestinal:
- Nausea and stomach discomfort (especially on an empty stomach — ironically, the same condition recommended for optimal absorption)
- Diarrhea
- Skin rash (allergic, uncommon)
- Headache
- Characteristic body/urine odor change (sulfur compounds)
Insulin Autoimmune Syndrome (IAS)
A rare but clinically significant adverse effect is insulin autoimmune syndrome (Hirata disease), which has been reported primarily in Japan and other Asian countries. ALA can trigger the production of insulin autoantibodies, leading to episodes of severe hypoglycemia. The mechanism is believed to involve ALA's sulfhydryl groups interacting with disulfide bonds on the insulin molecule, creating neoepitopes that provoke an immune response. While rare, this condition can be serious and difficult to diagnose without awareness of the association with ALA supplementation.
Hypoglycemia Risk
ALA's insulin-sensitizing effects can potentiate hypoglycemia in diabetic patients, particularly those on insulin or sulfonylurea medications. Blood glucose should be monitored more frequently when initiating ALA supplementation in diabetic patients, and medication doses may need adjustment.
Chelation-Related Risks
The Andy Cutler chelation community has documented specific risks associated with improper ALA chelation protocols:
- Mercury redistribution: taking ALA irregularly (missing doses, sporadic use) in individuals with mercury body burden can mobilize mercury from stable storage sites without maintaining the sustained blood levels needed to transport it to organs of excretion. This can potentially redistribute mercury to sensitive organs including the brain and kidneys, worsening symptoms rather than improving them
- Adrenal stress: chelation rounds can be physiologically stressful, and individuals with adrenal insufficiency may tolerate them poorly
- Mineral depletion: ALA chelates essential minerals (zinc, copper, magnesium) alongside toxic metals; supplementation with essential minerals is recommended during chelation protocols
Pediatric Toxicity
Fatal cases of ALA overdose have been reported in children, with lethal doses as low as approximately 25 mg/kg. In these cases, the clinical picture included severelactic acidosis, multi-organ failure, coagulopathy, and rhabdomyolysis. This underscores the importance of keeping ALA supplements out of reach of children.
Drug Interactions
- Diabetic medications: ALA can enhance hypoglycemic effects of insulin and oral hypoglycemics
- Thyroid medications (levothyroxine): ALA may affect thyroid hormone levels; take at separate times
- Chemotherapy agents (cisplatin): ALA's antioxidant properties may theoretically reduce the efficacy of oxidative-stress-dependent chemotherapy agents, though clinical significance is debated
Addiction Potential
Alpha-lipoic acid has zero addiction potential. It produces no euphoria, no reinforcing psychoactive effects, and no withdrawal syndrome upon discontinuation. It does not interact with dopaminergic reward pathways or any neurotransmitter system associated with addiction. It is not scheduled, controlled, or restricted as a substance of abuse in any jurisdiction. There are no documented cases of ALA dependence or compulsive use in the medical literature.
Overdose Information
Overdose Profile in Adults
Fatal ALA overdose in adults is extremely rare. The compound has a wide therapeutic index at supplement doses, and adults have tolerated single oral doses of several grams without fatal outcome. However, very high doses can produce clinically significant adverse effects:
- Severe nausea, vomiting, and diarrhea
- Hypoglycemia (particularly in diabetic patients or with concurrent insulin use)
- Lactic acidosis (from disruption of mitochondrial metabolism at toxic concentrations)
- Seizures (rare, at very high doses)
Pediatric Toxicity
ALA overdose in children is a more serious concern. Fatal cases have been reported at doses as low as approximately25 mg/kg. The clinical presentation of pediatric ALA overdose includes:
- Severe lactic acidosis (the primary cause of mortality)
- Multi-organ failure
- Disseminated intravascular coagulation (DIC)
- Rhabdomyolysis (muscle breakdown)
- Seizures
- Cardiovascular collapse
The mechanism of pediatric toxicity is believed to involve overwhelming disruption of mitochondrial metabolism and energy production at toxic ALA concentrations.
Insulin Autoimmune Syndrome
A unique "overdose" scenario is the development of insulin autoimmune syndrome (IAS/Hirata disease) with chronic ALA supplementation, where ALA-induced insulin antibodies cause episodes of severe, unpredictable hypoglycemia. This is not a dose-dependent overdose per se but an immunological reaction that can occur at standard supplement doses, primarily reported in individuals with specific HLA genotypes.
Treatment
- Adults: supportive care — antiemetics for nausea, glucose monitoring and supplementation for hypoglycemia, correction of metabolic acidosis with sodium bicarbonate, IV fluids
- Children: aggressive supportive care in a pediatric ICU setting — mechanical ventilation if needed, correction of lactic acidosis, management of coagulopathy (fresh frozen plasma, platelets), renal replacement therapy if indicated. The prognosis in severe pediatric cases can be poor despite aggressive treatment
- No specific antidote exists for ALA overdose
Tolerance
| Full | Does not develop |
| Half | N/A |
| Zero | N/A |
Cross-tolerances
Legal Status
Alpha-lipoic acid is legal worldwide as a dietary supplement and is available for over-the-counter purchase without prescription in the United States, European Union, Canada, Australia, Japan, and all other major jurisdictions. In the United States, it is classified as GRAS (Generally Recognized as Safe) by the FDA and is sold as a dietary supplement without restrictions. In Germany, ALA is available as both a prescription medication (Thioctacid, for diabetic neuropathy — covered by health insurance) and as an over-the-counter supplement. It is not a controlled substance, restricted substance, or regulated substance of any kind in any country. There are no quantity limitations or purchase restrictions for ALA anywhere in the world.
Tips (0)
No tips yet. Be the first to share one!